Sevgi Bilgic Eltan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sevgi Bilgic Eltan has a total of 273 co-authors. Here are the top co-authors by number of shared publications:
- Safa Baris
Marmara University
16 shared publications - Elif Karakoc-Aydiner
Pediatric Allergy and Immunology, Marmara University School of Medicine, Istanbul, Türkiye
11 shared publications - Ahmet Ozen
Division of Allergy and Immunology, Department of Pediatrics, School of Medicine, Marmara University, Istanbul, Turkey
10 shared publications - Ayca Kiykim
Department of Pediatric Allergy and Immunology, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye
7 shared publications - Royala Babayeva
Marmara University 1 Department of Pediatric Allergy and Immunology, Faculty of Medicine Istanbul
7 shared publications - Esra Yucel
Cerrahpasa Faculty of Medicine, Department of Pediatric Allergy and Immunology Istanbul University‐Cerrahpasa Istanbul Turkiye
5 shared publications
Latest Publications
- 2 November 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (11)
When cure is not enough: Parental anxiety, depression, and caregiver burden after HSCT for inborn errors of immunity
Introduction: Hematopoietic stem cell transplantation (HSCT) is curative for many children with inborn errors of immunity (IEIs). While research has largely focused on survival, immune reconstitution, and transplant‐related complications, the long‐term psychosocial impact on families of medically stable, complication‐free survivors remains poorly understood. Methods: In this cross‐sectional case–control study, 79 children with IEIs who achieved full immune reconstitution after HSCT and were free of chronic disease‐ or transplant‐related complications were compared with 69 age‐ and sex‐matched healthy controls. Parents completed the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and Zarit Burden Interview (ZBI). Caregivers also completed the parent‐report Strengths and Difficulties Questionnaire (SDQ). Linear regression analysis was performed to identify factors associated with caregiver burden. Results: Mothers of transplanted children had significantly higher depression, anxiety, and caregiver burden scores than control mothers (all p ≤ .001). Fathers demonstrated higher depression scores, whereas anxiety scores did not differ significantly. Maternal depression independently predicted caregiver burden ( β = .913, 95% CI 0.512–1.314, p < .001). Children in the patient group showed higher conduct problem and hyperactivity scores, with a trend toward greater internalizing difficulties. Psychological outcomes were not associated with demographic characteristics, disease‐related factors, or time since transplantation. Discussion: Despite successful immune reconstitution and the absence of chronic complications, families continued to experience substantial psychosocial burden. Maternal depressive symptoms emerged as the strongest determinant of caregiver burden. These findings suggest that medical recovery after HSCT does not necessarily translate into psychosocial recovery and support the integration of routine family‐centered psychological assessment into long‐term follow‐up care. image
- 2 November 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (11)
When cure is not enough: Parental anxiety, depression, and caregiver burden after HSCT for inborn errors of immunity
Introduction: Hematopoietic stem cell transplantation (HSCT) is curative for many children with inborn errors of immunity (IEIs). While research has largely focused on survival, immune reconstitution, and transplant‐related complications, the long‐term psychosocial impact on families of medically stable, complication‐free survivors remains poorly understood. Methods: In this cross‐sectional case–control study, 79 children with IEIs who achieved full immune reconstitution after HSCT and were free of chronic disease‐ or transplant‐related complications were compared with 69 age‐ and sex‐matched healthy controls. Parents completed the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and Zarit Burden Interview (ZBI). Caregivers also completed the parent‐report Strengths and Difficulties Questionnaire (SDQ). Linear regression analysis was performed to identify factors associated with caregiver burden. Results: Mothers of transplanted children had significantly higher depression, anxiety, and caregiver burden scores than control mothers (all p ≤ .001). Fathers demonstrated higher depression scores, whereas anxiety scores did not differ significantly. Maternal depression independently predicted caregiver burden ( β = .913, 95% CI 0.512–1.314, p < .001). Children in the patient group showed higher conduct problem and hyperactivity scores, with a trend toward greater internalizing difficulties. Psychological outcomes were not associated with demographic characteristics, disease‐related factors, or time since transplantation. Discussion: Despite successful immune reconstitution and the absence of chronic complications, families continued to experience substantial psychosocial burden. Maternal depressive symptoms emerged as the strongest determinant of caregiver burden. These findings suggest that medical recovery after HSCT does not necessarily translate into psychosocial recovery and support the integration of routine family‐centered psychological assessment into long‐term follow‐up care. image
- 19 October 2026
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 69 (1) , 86
Immune Checkpoint Dysfunction Remodels Adaptive Immune Receptor Repertoires in CTLA-4 Insufficiency and LRBA Deficiency
- 19 October 2026
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 69 (1) , 86
Immune Checkpoint Dysfunction Remodels Adaptive Immune Receptor Repertoires in CTLA-4 Insufficiency and LRBA Deficiency
- Open Access
- 13 June 2026
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 195 (5) , 2923-2930
Beyond immune recovery: Quality of life and psychosocial challenges in children with inborn errors of immunity after transplantation
Introduction: Hematopoietic stem cell transplantation (HSCT) provides definitive treatment for many inborn errors of immunity (IEI). Although most children achieve full immune reconstitution, long-term psychosocial and quality-of-life outcomes in medically stable survivors remain insufficiently understood. Methods: Children aged 8–18 years with IEI who achieved complete immune recovery and had no chronic complications were included. Quality of life and psychological status were evaluated using the Pediatric Quality of Life Inventory (PedsQL-C) and the Revised Children’s Anxiety and Depression Scale (RCADS). Healthy children matched for age, sex, and sociodemographic background served as controls. Results: Thirty-six patients and 41 controls participated. Children post-HSCT had significantly lower physical, psychosocial, and total quality-of-life scores (p = 0.022, 0.015, 0.006) and higher depression scores (p = 0.027). One-quarter of school-aged patients were not attending school, and one-third of families restricted exposure to crowded environments. Conclusion: Despite immune recovery, children remain vulnerable to psychosocial challenges. These findings support incorporation of routine psychological assessment and family counseling into long-term post-HSCT follow‑up.
- 13 June 2026
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 195 (5) , 2923-2930
Open AccessBeyond immune recovery: Quality of life and psychosocial challenges in children with inborn errors of immunity after transplantation
Introduction: Hematopoietic stem cell transplantation (HSCT) provides definitive treatment for many inborn errors of immunity (IEI). Although most children achieve full immune reconstitution, long-term psychosocial and quality-of-life outcomes in medically stable survivors remain insufficiently understood. Methods: Children aged 8–18 years with IEI who achieved complete immune recovery and had no chronic complications were included. Quality of life and psychological status were evaluated using the Pediatric Quality of Life Inventory (PedsQL-C) and the Revised Children’s Anxiety and Depression Scale (RCADS). Healthy children matched for age, sex, and sociodemographic background served as controls. Results: Thirty-six patients and 41 controls participated. Children post-HSCT had significantly lower physical, psychosocial, and total quality-of-life scores (p = 0.022, 0.015, 0.006) and higher depression scores (p = 0.027). One-quarter of school-aged patients were not attending school, and one-third of families restricted exposure to crowded environments. Conclusion: Despite immune recovery, children remain vulnerable to psychosocial challenges. These findings support incorporation of routine psychological assessment and family counseling into long-term post-HSCT follow‑up.
- Open Access
- 9 June 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (5) , e20250227
A homozygous CTLA-4 variant causes CTLA-4 deficiency with severe immune dysregulation
CTLA-4 is a critical immune checkpoint that maintains self-tolerance by regulating immune activation. Here, we describe the first case of homozygous CTLA-4 deficiency (CTLA4S172P/S172P), presenting with early-onset autoimmunity, lymphoproliferation, and growth failure. Immunological profiling revealed profound T- and B-cell dysregulation, characterized by T-cell hyperproliferation, a TH1-skewed helper T-cell phenotype, and expansion of activated and atypical B-cell subsets. The identified variant led to impaired CTLA-4 protein stability and enhanced lysosomal degradation, resulting in significantly reduced but still detectable total and surface expression and defective CD80 transendocytosis. Abatacept (CTLA-4-Ig) therapy effectively restored immune regulation and controlled disease activity. These findings expand the clinical and mechanistic spectrum of CTLA-4–related disorders, linking residual CTLA-4 function with the severity of immune dysregulation and emphasizing the therapeutic potential of targeted CTLA-4 modulation.
- 9 June 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (5) , e20250227
Open AccessA homozygous CTLA-4 variant causes CTLA-4 deficiency with severe immune dysregulation
CTLA-4 is a critical immune checkpoint that maintains self-tolerance by regulating immune activation. Here, we describe the first case of homozygous CTLA-4 deficiency (CTLA4S172P/S172P), presenting with early-onset autoimmunity, lymphoproliferation, and growth failure. Immunological profiling revealed profound T- and B-cell dysregulation, characterized by T-cell hyperproliferation, a TH1-skewed helper T-cell phenotype, and expansion of activated and atypical B-cell subsets. The identified variant led to impaired CTLA-4 protein stability and enhanced lysosomal degradation, resulting in significantly reduced but still detectable total and surface expression and defective CD80 transendocytosis. Abatacept (CTLA-4-Ig) therapy effectively restored immune regulation and controlled disease activity. These findings expand the clinical and mechanistic spectrum of CTLA-4–related disorders, linking residual CTLA-4 function with the severity of immune dysregulation and emphasizing the therapeutic potential of targeted CTLA-4 modulation.
- 30 November 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (8) , e70234
Successful Use of Haploidentical HSCT in a Child With Schimke Immuno‐Osseous Dysplasia Who Developed PTLD After Kidney Transplantation
Background: Schimke Immuno‐Osseous Dysplasia Is a Rare Autosomal Recessive Multisystem Disorder Caused by Biallelic Pathogenic Variants in the SMARCAL1 Gene, Which Encodes a DNA Annealing Helicase Essential for Replication Fork Stability and Genomic Maintenance. Loss of SMARCAL1 Function Leads to Genomic Instability, Resulting in a Characteristic Clinical Triad of Disproportionate Short Stature, Steroid‐Resistant Nephrotic Syndrome and Immunodeficiency. Kidney Transplantation Is the Standard Treatment for End‐Stage Renal Disease in Schimke Immuno‐Osseous Dysplasia. However, the Underlying Genomic Fragility and Immunodeficiency Heighten the Risk of Post‐Transplant Complications, Particularly Epstein–Barr Virus‐Associated Post‐Transplant Lymphoproliferative Disorder. Method: We Report the Case of a 7‐Year‐Old Girl With Genetically Confirmed Schimke Immuno‐Osseous Dysplasia Who Developed Epstein–Barr Virus‐Positive Diffuse Large B‐Cell Lymphoma Eight Months Following Maternal Kidney Transplantation, Despite Reduced‐Intensity Immunosuppression. Rituximab Therapy Resulted in Complete Remission, but Required the Withdrawal of all Immunosuppressive Agents, Thereby Posing a Risk of Kidney Graft Loss. Result: In the Context of Primary Immunodeficiency and the Development of Post‐Transplant Lymphoproliferative Disorder in Such a Setting, the Patient Subsequently Underwent Haploidentical Hematopoietic Stem Cell Transplantation From the Mother, Using an αβ T‐Cell‐Depleted Graft and a Nephrotoxicity‐Sparing Conditioning Regimen. Full Donor Chimerism Was Achieved by Day 28. Immune Reconstitution Occurred Within One Year. At 27 Months After Hematopoietic Stem Cell Transplantation She Remains in Remission With Preserved Kidney Function and no Ongoing Immunosuppression. Conclusion: This Case Highlights the Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation as a Curative Salvage Strategy for Immunosuppression‐Free Survival After Kidney Transplantation in Patients With Schimke Immuno‐Osseous Dysplasia.
- 30 November 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (8) , e70234
Successful Use of Haploidentical HSCT in a Child With Schimke Immuno‐Osseous Dysplasia Who Developed PTLD After Kidney Transplantation
Background: Schimke Immuno‐Osseous Dysplasia Is a Rare Autosomal Recessive Multisystem Disorder Caused by Biallelic Pathogenic Variants in the SMARCAL1 Gene, Which Encodes a DNA Annealing Helicase Essential for Replication Fork Stability and Genomic Maintenance. Loss of SMARCAL1 Function Leads to Genomic Instability, Resulting in a Characteristic Clinical Triad of Disproportionate Short Stature, Steroid‐Resistant Nephrotic Syndrome and Immunodeficiency. Kidney Transplantation Is the Standard Treatment for End‐Stage Renal Disease in Schimke Immuno‐Osseous Dysplasia. However, the Underlying Genomic Fragility and Immunodeficiency Heighten the Risk of Post‐Transplant Complications, Particularly Epstein–Barr Virus‐Associated Post‐Transplant Lymphoproliferative Disorder. Method: We Report the Case of a 7‐Year‐Old Girl With Genetically Confirmed Schimke Immuno‐Osseous Dysplasia Who Developed Epstein–Barr Virus‐Positive Diffuse Large B‐Cell Lymphoma Eight Months Following Maternal Kidney Transplantation, Despite Reduced‐Intensity Immunosuppression. Rituximab Therapy Resulted in Complete Remission, but Required the Withdrawal of all Immunosuppressive Agents, Thereby Posing a Risk of Kidney Graft Loss. Result: In the Context of Primary Immunodeficiency and the Development of Post‐Transplant Lymphoproliferative Disorder in Such a Setting, the Patient Subsequently Underwent Haploidentical Hematopoietic Stem Cell Transplantation From the Mother, Using an αβ T‐Cell‐Depleted Graft and a Nephrotoxicity‐Sparing Conditioning Regimen. Full Donor Chimerism Was Achieved by Day 28. Immune Reconstitution Occurred Within One Year. At 27 Months After Hematopoietic Stem Cell Transplantation She Remains in Remission With Preserved Kidney Function and no Ongoing Immunosuppression. Conclusion: This Case Highlights the Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation as a Curative Salvage Strategy for Immunosuppression‐Free Survival After Kidney Transplantation in Patients With Schimke Immuno‐Osseous Dysplasia.
- 16 May 2025
- Published by Springer Nature in Immunologic Research
- Vol. 73 (1) , 1-5
Identification of nonsense variants in the ATM gene mimicking SCID phenotype: a brief report
Severe combined immunodeficiency (SCID) represents a life-threatening inborn error of immunity, necessitating rapid diagnosis and intervention to prevent fatal outcomes. While SCID is characterized by profound T-cell lymphopenia, it may overlap with other conditions like ataxia-telangiectasia (AT), which also presents with T-cell deficiencies. This study examines two cases of suspected SCID in infants, later identified as AT due to pathogenic variants in the ATM gene. Despite initial negative results from SCID-targeted gene panels, further genetic testing revealed nonsense mutations (p.Y2036X and p.E1996X) in the FAT domain of the ATM gene, confirmed by Sanger sequencing. The patients exhibited significant T-cell lymphopenia and reduced ATM protein activity, indicative of AT. These findings highlight the importance of comprehensive genetic screening beyond common SCID-associated genes, especially in patients with atypical presentations. Early and accurate diagnosis can prevent mismanagement and guide appropriate therapies, improving patient outcomes.
- 16 May 2025
- Published by Springer Nature in Immunologic Research
- Vol. 73 (1) , 1-5
Identification of nonsense variants in the ATM gene mimicking SCID phenotype: a brief report
Severe combined immunodeficiency (SCID) represents a life-threatening inborn error of immunity, necessitating rapid diagnosis and intervention to prevent fatal outcomes. While SCID is characterized by profound T-cell lymphopenia, it may overlap with other conditions like ataxia-telangiectasia (AT), which also presents with T-cell deficiencies. This study examines two cases of suspected SCID in infants, later identified as AT due to pathogenic variants in the ATM gene. Despite initial negative results from SCID-targeted gene panels, further genetic testing revealed nonsense mutations (p.Y2036X and p.E1996X) in the FAT domain of the ATM gene, confirmed by Sanger sequencing. The patients exhibited significant T-cell lymphopenia and reduced ATM protein activity, indicative of AT. These findings highlight the importance of comprehensive genetic screening beyond common SCID-associated genes, especially in patients with atypical presentations. Early and accurate diagnosis can prevent mismanagement and guide appropriate therapies, improving patient outcomes.
- Open Access
Comprehensive αβ T‐Cell Receptor Repertoire Analysis Reveals a Unique CD8+ TCR Landscape in DOCK8‐Deficient Patients
Background: Dedicator of cytokinesis protein 8 (DOCK8) is a guanine nucleotide exchange factor highly expressed in, and critical for, the function of various innate and adaptive immune cells. DOCK8 deficiency leads to combined immunodeficiency characterized by susceptibility to infections, autoimmunity, and a severe Th2‐type immune response. While dysfunction in various T cell subsets has been implicated in these phenotypes, a comprehensive analysis of the T‐cell receptor (TCR) repertoire in these patients has not yet been documented. This study investigates the αβ TCR repertoire in DOCK8‐deficient patients to identify features related to disease pathogenesis and explore the potential role of TCR repertoire alterations in disease development.Methods: We compared immune repertoire profiles determined by high‐throughput TCR sequencing of circulating CD4+ and CD8+ T cells from patients with DOCK8 deficiency (n = 10) to healthy controls (n = 7) and patients with ataxia‐telangiectasia (AT) (n = 5).Results: Different diversity analyses revealed a restricted TRA and TRB repertoire in both CD4+ and CD8+ T cells from DOCK8‐deficient patients, with the restriction being more pronounced in CD8+ T cells. Skewed usage of individual variable (V) and joining (J) genes and potentially self‐reactive CD8+ T cell clones, as determined by hydrophobicity and cysteine indices, were identified in DOCK8‐deficient patients.Conclusion: Our study represents the most comprehensive immune repertoire analysis in DOCK8 deficiency. The identification of a significantly restricted αβ TCR repertoire, along with the detection of potentially autoreactive clones, highlights the crucial role of immune repertoire profiling in elucidating the pathogenesis of DOCK8 deficiency.
Open AccessComprehensive αβ T‐Cell Receptor Repertoire Analysis Reveals a Unique CD8+ TCR Landscape in DOCK8‐Deficient Patients
Background: Dedicator of cytokinesis protein 8 (DOCK8) is a guanine nucleotide exchange factor highly expressed in, and critical for, the function of various innate and adaptive immune cells. DOCK8 deficiency leads to combined immunodeficiency characterized by susceptibility to infections, autoimmunity, and a severe Th2‐type immune response. While dysfunction in various T cell subsets has been implicated in these phenotypes, a comprehensive analysis of the T‐cell receptor (TCR) repertoire in these patients has not yet been documented. This study investigates the αβ TCR repertoire in DOCK8‐deficient patients to identify features related to disease pathogenesis and explore the potential role of TCR repertoire alterations in disease development.Methods: We compared immune repertoire profiles determined by high‐throughput TCR sequencing of circulating CD4+ and CD8+ T cells from patients with DOCK8 deficiency (n = 10) to healthy controls (n = 7) and patients with ataxia‐telangiectasia (AT) (n = 5).Results: Different diversity analyses revealed a restricted TRA and TRB repertoire in both CD4+ and CD8+ T cells from DOCK8‐deficient patients, with the restriction being more pronounced in CD8+ T cells. Skewed usage of individual variable (V) and joining (J) genes and potentially self‐reactive CD8+ T cell clones, as determined by hydrophobicity and cysteine indices, were identified in DOCK8‐deficient patients.Conclusion: Our study represents the most comprehensive immune repertoire analysis in DOCK8 deficiency. The identification of a significantly restricted αβ TCR repertoire, along with the detection of potentially autoreactive clones, highlights the crucial role of immune repertoire profiling in elucidating the pathogenesis of DOCK8 deficiency.
The Discrepancy Between Perceived and Proven Drug Hypersensitivity in a Well‐Defined Cohort of Patients With Inborn Errors of Immunity
Background: Inborn errors of immunity ( IEI ) are genetic disorders characterized by recurrent and/or severe infections, autoimmunity, autoinflammation, allergies, and cancer. Despite frequent drug exposures due to recurrent infections and comorbidities, the prevalence and characteristics of drug hypersensitivity reactions ( DHR ) in pediatric patients with IEI remain understudied. Methods: This multicenter, cross‐sectional study evaluated 264 pediatric patients with IEI along with a control group ( CG ) comprising 443 age‐matched controls using a stepwise diagnostic approach, including the patient‐reported Study Questionnaire (Study‐Q), the European Network for Drug Allergy Questionnaire ( ENDA ‐Q), and confirmatory diagnostic testing, including skin testing and drug provocation tests ( DPT ). The demographic, clinical, and allergic profiles of the IEI patients and CG were compared. Results: IEI patients (57.6% male) had a median current age of 10 years, with combined immunodeficiencies being the most common phenotype (53.4%). The number of courses for antibiotic use and hospitalization was more frequent in IEI patients compared to CG ( p < 0.001). DHR was more common in IEI patients according to Study‐Q ( p < 0.001) and ENDA ‐Q ( p = 0.002), although proven DHR as a result of confirmatory testing was comparable with CG (1.1% vs. 0.4%, p = 0.368). Despite the fact that suspected DHR in IEI patients was most frequently associated with beta‐lactams (47.6%), with 73.9% presenting with urticaria, proven DHR mainly included reactions to radiocontrast agents ( n = 2) and ibuprofen ( n = 1). Conclusion: Although drug hypersensitivity is often suspected in patients with IEI , proven cases are rare. Standardized protocols, including DPT in drug allergy centers, are essential to differentiate proven allergies from nonallergic reactions, ensure effective treatment, and avoid unnecessary drug restrictions in this unique population.
The Discrepancy Between Perceived and Proven Drug Hypersensitivity in a Well‐Defined Cohort of Patients With Inborn Errors of Immunity
Background: Inborn errors of immunity ( IEI ) are genetic disorders characterized by recurrent and/or severe infections, autoimmunity, autoinflammation, allergies, and cancer. Despite frequent drug exposures due to recurrent infections and comorbidities, the prevalence and characteristics of drug hypersensitivity reactions ( DHR ) in pediatric patients with IEI remain understudied. Methods: This multicenter, cross‐sectional study evaluated 264 pediatric patients with IEI along with a control group ( CG ) comprising 443 age‐matched controls using a stepwise diagnostic approach, including the patient‐reported Study Questionnaire (Study‐Q), the European Network for Drug Allergy Questionnaire ( ENDA ‐Q), and confirmatory diagnostic testing, including skin testing and drug provocation tests ( DPT ). The demographic, clinical, and allergic profiles of the IEI patients and CG were compared. Results: IEI patients (57.6% male) had a median current age of 10 years, with combined immunodeficiencies being the most common phenotype (53.4%). The number of courses for antibiotic use and hospitalization was more frequent in IEI patients compared to CG ( p < 0.001). DHR was more common in IEI patients according to Study‐Q ( p < 0.001) and ENDA ‐Q ( p = 0.002), although proven DHR as a result of confirmatory testing was comparable with CG (1.1% vs. 0.4%, p = 0.368). Despite the fact that suspected DHR in IEI patients was most frequently associated with beta‐lactams (47.6%), with 73.9% presenting with urticaria, proven DHR mainly included reactions to radiocontrast agents ( n = 2) and ibuprofen ( n = 1). Conclusion: Although drug hypersensitivity is often suspected in patients with IEI , proven cases are rare. Standardized protocols, including DPT in drug allergy centers, are essential to differentiate proven allergies from nonallergic reactions, ensure effective treatment, and avoid unnecessary drug restrictions in this unique population.
- Open Access
- 28 March 2025
- Published by Marmara University in Clinical and Experimental Health Sciences
- Vol. 15 (1) , 217-225
Cross-sectional Analysis of Health Quality, Treatment Satisfaction and Adherence in Children with Food Allergy
Objective: To evaluate treatment adherence, satisfaction, and disease-specific health-related quality of life (HRQL) in children aged 0-12 years with FA and their parents. Methods: A cross-sectional study was conducted with 100 children diagnosed with FA by a physician who required allergen avoidance. Parents completed the Food Allergy Quality of Life Questionnaire Parent Form (FAQLQ-PF), Food Allergy Parent Questionnaire (FAPQ), Treatment Satisfaction Questionnaire (TSQM-9), and Modified Morisky Scale (MMS). Demographic and clinical data were obtained. Results: The median total score for FAQLQ-PF was 39 (IQR 26-54), indicating moderate impairment in QoL. Emotional impact and social/dietary limitations were notably higher in children older than five years and those with multiple FA. The median FAPQ score was 38 (IQR 29-49), reflecting moderate parental stress and anxiety. Treatment satisfaction (TSQM-9) had a median score of 57 (IQR 41-71), with higher scores for parents of children with multisystem involvement. Treatment adherence (MMS) had a median score of 83 (IQR 67-100), indicating good overall adherence. Significant correlations were observed between higher parental anxiety and lower QoL. Conclusion: Children with FA and their parents experience significant HRQL impairment, stress, and varying levels of satisfaction with treatment. These results underscore the necessity for comprehensive management strategies that encompass psychosocial support and personalized interventions to enhance outcomes for families dealing with FA.
- 28 March 2025
- Published by Marmara University in Clinical and Experimental Health Sciences
- Vol. 15 (1) , 217-225
Open AccessCross-sectional Analysis of Health Quality, Treatment Satisfaction and Adherence in Children with Food Allergy
Objective: To evaluate treatment adherence, satisfaction, and disease-specific health-related quality of life (HRQL) in children aged 0-12 years with FA and their parents. Methods: A cross-sectional study was conducted with 100 children diagnosed with FA by a physician who required allergen avoidance. Parents completed the Food Allergy Quality of Life Questionnaire Parent Form (FAQLQ-PF), Food Allergy Parent Questionnaire (FAPQ), Treatment Satisfaction Questionnaire (TSQM-9), and Modified Morisky Scale (MMS). Demographic and clinical data were obtained. Results: The median total score for FAQLQ-PF was 39 (IQR 26-54), indicating moderate impairment in QoL. Emotional impact and social/dietary limitations were notably higher in children older than five years and those with multiple FA. The median FAPQ score was 38 (IQR 29-49), reflecting moderate parental stress and anxiety. Treatment satisfaction (TSQM-9) had a median score of 57 (IQR 41-71), with higher scores for parents of children with multisystem involvement. Treatment adherence (MMS) had a median score of 83 (IQR 67-100), indicating good overall adherence. Significant correlations were observed between higher parental anxiety and lower QoL. Conclusion: Children with FA and their parents experience significant HRQL impairment, stress, and varying levels of satisfaction with treatment. These results underscore the necessity for comprehensive management strategies that encompass psychosocial support and personalized interventions to enhance outcomes for families dealing with FA.